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Abstract  
BACKGROUND: The American Joint Committee on Cancer (AJCC’s) skin melanoma surgical treatment 
recommendations from 2011 are characterised by a prima facie "freedom of choice" regarding how extensive 
should be the excisions for melanomas with tumour thickness up to 2 mm and melanoma in situ. It is unclear why 
the recommended surgical security margins vary between 0.5 and 1 cm for melanoma in situ, whereas for 
melanomas with a tumour thickness of up to 1.99 mm, the range of variation is also between 1 and 2 cm, without 
specifying when the surgical field should be broader and, narrower, accordingly. This "uncertainty or lack of intent" 
of the guilders often leads to the same surgical approach to melanomas at different stages, or to a different 
approach in cases of melanomas at the same stage, in contrast. Therefore, this should be defined as wrong, 
logically.  
CASE PRESENTATION: We present 3 patients with cutaneous melanomas, treated with similar fields of surgical 
security. Current issues, generated within the framework of melanoma’s surgery guided by the recommendations 
of the AJCC are also discussed. A new surgical approach in patients with melanoma is recommended, discussed 
for the first time in world literature. We hypothesize that the introduction of a certain recommendations for a 2 cm 
surgical field in all directions during the initial excision, combined with the parallel performance of a sentinel lymph 
node biopsy, will lead in fact to several important advantages: 1) avoiding of the secondary excision in at least 
70% - 90% of the patients (depending on the tumor thickness), 2) minimizing the risk of lymphatic effusion change 
and misinterpretation of the sentinel lymph node biopsy’s results in patients with secondary excision; 3) 
optimization of the surgical team’s work; 4) minimizing the possibility of unprepared/uninformed personnel to take 
part in decisions for treating a specific disease such as skin melanoma, 4) facilitating the appropriate patients’ 
group selection at the appropriate stage when involving them in different studies, leading to equal leveling of the 
initial positions; 
CONCLUSION: Whether the proposed approach will be subjected to a detailed discussion of AJCC’s expert’s 
remains currently unclear. 
 
 
 
 
Introduction 
 
Guideline as a term, resulting in choice of 
treatment regimen (variety of decisions)  
A guideline is a statement by which to 
determine a course of action [1]. A guideline aims to 
streamline particular processes according to a set 
routine or sound practice [1]. By definition, following a 
guideline is never mandatory [1]. Guidelines are not 
binding and are not enforced [1].
 
Because of the highlighted possibility of 
variability in interpretation of the guidelines, as a rule, 
they generate some problems, which require special 
attention, regarding the improvement of patients’ 
overall survival rate. Guidelines should be able to 
specify their recommendations, based on the new 
proposals if they are well-explained and justified.  
Guidelines are either followed or ignored (as 
they are recommended, not mandatory). In the case 
of their complete ignorance, however, the 
explanations of the "sinners" or the non-observers 
should be at least somehow logically explained. 
Hence the questions - why should I follow the 
guidelines, when there are only recommendations? 
Can no one obligate me? The included possibility for 
variable interpretation of the recommended 
parameters raises some problems in determining the 
appropriate surgical safety margins, in practice. 
Whether this permissible variety is logically based and 
widely acceptable remains unclear.  
 
Guidelines’ disadvantages 
The provided possibility of variations in the 
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interpretations of the guidelines, weaken the weight of 
the surgeon’s decisions who try to follow them, 
although they are not obliged, above all protect from 
the "mistakes" that may follow. Despite that the 
freedom of the clinician's decisions should be 
provided, in cases of oncological diseases, it should 
also be: 1) requiring of more responsibility for the 
clinician 2) obligating him for strictly following the 
recommendations for a certain periods of time (at 
least until the next update of the guidelines) 3) 
requiring a maximal support and reasonably useful for 
the patient, by reducing the number of excisions, for 
example. About these important points, it could be 
concluded that American Joint Committee on Cancer 
(AJCC’s) proposed melanoma’s treating guidelines 
from 2011 needs a serious rethinking, more frequent 
renewal, and rigorous follow-up [2]. 
 
Critical comments on certain 
recommendations in the guideline of 
melanoma’s management 
The treatment of cutaneous melanoma 
consists in the initial performance of an excision 
biopsy or excision with a surgical field of 0.3-0.5 cm in 
all directions. The further decision for re-excision with 
additional safety margins should be considered based 
on the result from histopathological micro-staging and 
tumour thickness. If the initially measured tumour 
thickness is between 1 and 2 mm, the surgical field 
should be extended by 1 cm in all directions, no 
matter the size of the initially obtained surgical field.  
While there is no precise opinion on this issue 
in the AJCC's recommendations, most of the 
dermatologic surgeons measure an additional 1 cm 
field. However, it is unclear why and when AJCC’s 
guideline recommends the size of a surgical field 
between 1 and 2 cm in the same tumour thickness, 
namely 1-2 mm (2)? Unlike German guidelines strictly 
requiring of a certain field of 1 cm in all directions, the 
American ones allow variations? 
On another hand, the performance of a 
sentinel lymph node biopsy, followed by a re-excision 
of the primary tumor (with the adequate area of 
surgical safety that should not exceed 2 cm) is 
obligatory when there are other two constellations, 
namely: 1) a tumor thickness above 1 mm; or 2) a 
tumor thickness below 1 mm with additional risk 
factors such as: age under 40, vessel or lymphatic 
invasion, increased number of mitosis, presence of 
ulceration.  
The categorical opinion of some experts in the 
field, for example, is that the performance of sentinel 
lymph node biopsy and secondary excision should not 
exceed 2 weeks after the primary excision, no matter 
of the applied surgical technique. This is difficult to be 
performed in practice (at the national level at least), 
regarding the fact that obtaining of the primitive 
histology requires at least 10 days up to a month. 
Furthermore, even after obtaining the result, patients 
want to consult themselves with other specialists who 
take additional time. The oncologic committee’s 
decision should be also awaited before the patient is 
referred to the oncology centre for a further sentinel 
lymph node biopsy and secondary excision. 
If the primary care unit is not oncological, the 
delay in these procedures is inevitable or very likely 
(focus on the national level), which makes the 
reaching of the 2-weeks deadline impossible. 
Therefore, the loss of this precious time should be 
optimised and precise on a national level at least.  
Another significant problem is the histological 
evaluation, which is unsatisfactory and needs 
optimisation in the majority of cases (national level). 
The following points should be improved; 1) Better 
control of the tumor thickness measurement after the 
primary excision, and 2) Refinement of the 
histopathological reports, obtaining accurate data on 
the number of mitosis, the presence of ulceration, the 
absence or presence of vessels or lymphatic invasion, 
the satellites, state of the resection lines, etc., which is 
of a great importance for melanomas with tumor 
thickness less than 1 mm and 0.8 mm, as these are 
considered to be additional important criteria for 
performance of a sentinel lymph nodes biopsy.  
The lack of this data does not assist the 
clinician in selecting patients for further sentinel lymph 
node removal, neither assist in improving the survival 
rate.  
The question why according to AJCC’s 2011 
recommendations, the melanoma in situ is removed 
with a field of surgical safety equivalent to the former, 
applied to aggressive thin melanomas below 1 mm, 
which also requires additional removal of the sentinel 
lymph node, remains open? The lack of logic or data 
on the issue should not bind the experts' hands for 
adequate solutions at clearly defined micro-staging. 
After thorough interpretation of the AJCC’s 
melanoma guidelines from 2011 [2], it should be 
concluded that the surgical treatment of this type of 
tumour is unclear explained and supported and 
requires serious criticism. The following controversial 
claims are defined in the guideline [2]:  
“The primary treatment modality for cutaneous 
melanoma is surgical excision [2]. After the diagnosis 
of melanoma has been histologically confirmed 
and the primary lesion has been adequately micro 
stage, a wider and frequently deeper excision is 
needed to ensure complete removal [2]. It is 
recognized that melanoma cells may extend 
subclinically several millimeters to several centimetres 
beyond the clinically visible lesion [1]. Recommended 
surgical margins are based partly on prospective 
randomised controlled trials and partly on 
consensus opinion when no prospective data 
exist [2].“  
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“It is essential to recognise that surgical 
margin recommendations are based on studies in 
which margins were clinically measured around the 
primary tumour and may not correlate with 
histologically measured tumor-free margins. “  
It turns out that regardless of clinically 
measured distances of 2 cm from the tumour tissue, in 
practice, the histological distances would be 
significantly smaller? Doesn’t it require: 1) an 
aggressive initial approach? Doesn’t this comment in 
practice include the very decision for significant 
change of the recommendations? What should we do 
if the fields of the clinically measured and 
histologically proven fields of safety surgical distance 
differ significantly? And 2) the logic requires 
immediate re-exercises, whether primary or 
secondary excision. This is the only way that patients 
could be identified and treated according to the 
guidelines, and then their data could also be used in 
future studies. Going further, why are we always 
accurate in completing and enrolling melanoma 
patients into a variety of expensive surveys instead of 
focusing on clearing out the starting positions that are 
likely to generate future problems? 
The question why the clinically measured 
distances in healthy tissue or the so-called resection 
margins should not be equivalent to histologically 
measured remains also open [2]: 
"Treatment of choice for primary cutaneous 
melanoma of any thickness is surgical excision with 
histologically negative margins. Surgical margins for 
invasive melanoma should be at least 1 cm and no 
more than 2 cm clinically measured around 
primary tumour; clinically measured surgical margins 
do not need to correlate with histologically negative 
margins. For melanoma in situ, wide excision with 
0.5- to 1.0-cm margins is recommended; lentigo 
malignant histologic subtype may require [0.5-cm 
margins to achieve histologically negative margins, 
because of characteristically broad subclinical 
extension." 
Even "more unstable” are the following 
experts’ recommendations [2]:  
“Based on available evidence and consensus 
opinion, the expert work group recommends that 
primary melanomas 1.01 to 2.0 mm in thickness are 
widely excised with 1- to 2-cm margins [1]. However, 
clear evidence is not available, and final surgical 
margins may vary based on tumour location and 
functional or cosmetic considerations [3-7].“  
Unfortunately, in the AJCC’s „variable surgical 
margins“ recommendations, there is no indication of 
who defines the concepts as "unpleasant or 
unacceptable for a tumour location surgery," and who 
makes the final decision whether the "reduced" 
surgical safety fields are aesthetically pleasing? Does 
the patient or therapist decide this? In practice, the 
recommendations leave an absolute freedom in the 
dermatologist's decisions regarding the choice of the 
resection field [2], while he still has the right to be 
influenced by the patient‘s opinion and desire. What 
surgical safety field should be applied in cases of 
tumours over 1 mm thickness- 1 or 2cm? Why should 
we operate melanomas with a thickness of 1, 01 mm 
and those with 4 mm and more mm in the same way 
then (2 cm in all directions) [2]? The same situation is 
obtained with tumours with 1.9 mm thickness and 
melanoma in situ (1 cm in all directions)? Even the 
histopathological type of the melanoma is not included 
into consideration [2]? Therefore, this histological 
"substaging" could be at least a "gateway" for the 
guideline formating. The question remains open: Are 
the decisions of the US experts' group always the right 
ones? 
The psychological and physical pressure of 
the patients during these interventions is also 
significant, and furthermore some of them could not 
be follow up for one or another reason (loss of trust for 
example due to 1) reading the recommendations on 
the internet and/or 2) lack of clear explanation for one 
or another field of surgical safety, 3) progression of 
the disease in cases of patients with the same tumor 
thickness, but different field of surgical safety). So 
would it be advisable or at least logically determined 
wider resection fields, firmly stated according to 
guidelines? Don’t we need guidelines that provide 
more accurate recommendations instead of a 
variation of choice [2]? 10 years ago, experts 
considered that the initial tumours should be excited 
with a small field of surgical safety, without plastic 
reconstruction, as it could alternate the lymph flow. It 
is now considered that whether or not plastic 
reconstruction for initial defect closure is performed, 
the performance of sentinel lymph node biopsy 
followed by re-excision is necessary for 2 weeks of 
the period. Perceptions of melanoma’s surgery are 
quite dynamic. The question remains: isn’t it better to 
perform: 1) ultrasound of the tumour thickness 
providing the decision for a single surgical 
intervention, namely: simultaneous removal of the 
sentinel lymph node and a primary tumour? Therefore 
the lymph flow would be at least modified and patients 
would get the maximum profits. The experts' response 
in these cases would probably be: "We should be 
humans, we can not apply invasive methodologies 
and approaches in the uncertainty of what are the 
tumour thickness?" Our answer would be: "What were 
you up to now?" 
It would be logical to ask the following: Is the 
prognosis of patients with melanoma in situ and those 
with a tumour thickness of 1.99 mm uniform? AJCC’s 
guidelines indirectly support the absurd thesis of 
inadequate melanoma treatment at different stages 
[2]. Isn’t that also the clue, regarding the controversial 
results of the various studies around the world 
concerning the survival and recurrence rate in 
general? 
The freedom of the surgeon’s interpretation of 
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the AJCC's recommended resection fields [2] is 
embarrassing and at the very least needs rethinking! 
The critical insight into internationally established 
criteria should not be inevitably crossed out, but 
should give rise to a more in-depth analysis of the 
actual criteria and their rethinking and pre-definition, 
instead! "Variability" is unlikely to lead to progress and 
success in oncology. We should remember that 
scientific results are unthinkable without strict initial 
data or, in other words, without unification of the 
starting positions of the cases. The experts’ 
comments themselves show that radicality in the 
surgical approach is the key point to overall 
melanoma survival [2]. Billions could not be invested 
in future projects on targeted therapy, for example, 
including patients in different stages who treated with 
equal approaches or patients in the same stage but 
treated with different approaches in contrast.  
Referring to the AJCC's recommendations, 
the following statements are also interesting although 
not considered in creating their recommendations, 
even supported by serious studies [2]: 
"In melanomas thicker than 2.0 mm, one 
study found that narrow excision with 1-cm margin 
was associated with a somewhat higher combined 
local, regional, and nodal recurrence rate than wider 
excision with 3-cm margin [4, 8]." 
Why the following is also not taken into 
consideration? 
"Several other studies have found slightly 
higher local recurrence rates for melanomas thicker 
than 1 mm treated with narrow excision with a 1-cm 
margin versus a wider excision with a 3-cm margin 
[9]." 
Why are wider surgical fields not 
recommended then? Why does the classification give 
scope for flexibility and variability? Who is interested 
in data not being standardised, resulting in full chaos? 
And then the experts wonder how within the 
different double-blind, multicentric, randomised etc. 
studies, expectations and results do not match or 
there is no explanation for them? Or perhaps the "era 
of melanoma surgical therapy variability" occurred? 
Freedom of treatment with different resection fields, 
although data supporting both of the theories are 
available? The term "clear positioning" should be 
more seriously implicated in the AJCC's guidelines. 
It is unclear how data are presented in AJCC 
from 2011 to nowadays which are not taken into 
account, despite the categorical need for wider 
excision fields? 
 
Resection margins - a need for 
revolutionary thinking 
In addition to the needed standardisation of 
the material and methods for scientific studies, 
reconsideration of the resection fields should also be 
done for another purpose: reducing the number of 
secondary excisions. Secondary excisions are 
generally at least as severe as the initially performed 
and more burdensome for the patients themselves. 
Often, dermatologists face unpleasant patient’s 
question: 
"Doctor, why the initial surgical field was not 
safety and wide enough?  
Another interesting case, reported by patient:  
"I saw on the web that the melanomas should 
be removed with a surgical excision margins ranging 
between 1 and 2 cm, recommended by the experts. 
My tumour is 1.5 mm in thickness, the patient’s next to 
me is also 1.5 mm, but he had a bigger scar and had 
been operated with a 2 cm security field, while I had 
been operated with a 1 cm surgical security 
margin…Why? And furthermore, why is he alive and 
healthy second year after the surgery, while I'm full of 
metastases? " 
Are these questions answered in the AJCC’S 
guidelines? 
These dilemmas provoke not only the patients 
to think about the humanity of the established 
guidelines and the choice of a therapeutic approach. 
Isn’t it better to operate with a larger initial field of 
surgical safety, namely one of a minimum of 2 cm, 
with parallel performances of a sentinel lymph node 
removal? Which, in turn, would be beneficial to 
patients’ physical and psychical relieve, not only in 
early-stage melanomas but also in more advanced 
stages. Clearing of these "inaccuracies” would 
certainly result in profiling of all of the involved 
patients and physicians. There will be no future if we 
do not understand the past. And when it is unclear, 
the best thing would be to try to clear it out by clearing 
the mistakes. Our past will always reflect on our 
present and future. 
This way will inevitably optimise the work of 
the qualified staff with the lack of secondary excision. 
In practice, in tumours with a tumour thickness of 
more than 1 mm and above 2 mm, the optimal choice 
would always be a solid field of surgical safety of 2 cm 
while the draining lymph node is removed during the 
same session! 
On the other hand, we should also think about 
the fact that the patients themselves do not always 
agree with a secondary excision and do not appear 
regularly for second excisions and sentinel lymph 
node evaluation. Logically, the more aggressive initial 
pattern of behaviour in these patients should also 
yield better long-term outcomes, regarding the overall 
survival. Even for a limited number of patients, this 
approach would be beneficial. 
From the philosophically point of view, we 
would ask the question: "Isn’t it better to drink your 
coffee on the square, even with more severe scars or 
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even lymphedema (?), instead of the lack of this 
opportunity at all?" 
Unfortunately, the guidelines and the 
possibility of their variability determine at the current 
moment the possibility for NOT drinking of "just that 
cup of coffee"! 
Another serious question is whether pre-
operative measurement of tumour thickness 
ultrasonographically should be mandatory implicated? 
Why ultrasound measurement of tumour thickness is 
recommended, but does not belong to the "gold 
standard" or mandatory recommendations for clinical 
behaviour in the AJCC guidelines? These are the 
issues that should impose important solutions and 
narrower limits of variability within the AJCC 
recommendations. 
 
 
Presentation of Cases 
 
We present 3 interesting cases of patients 
with cutaneous melanoma, where the tumor thickness 
was not measured by ultrasound prior the initial 
excisions, but the diagnosis was made clinically and 
dermoscopic ally, while the choice of a surgical field is 
based on multiple factors, not at least, considered with 
patient’s opinions (Fig. 1-3). The clinically suggested 
tumour thickness was confirmed histologically in both 
of the cases, post surgically. 
 
Figure 1: 1а) Female patient with achromatic melanoma in the neck 
area occurred on a giant congenital melanocytic nevus. A local 
excision has been done and the histopathology confirmed the 
diagnosis of malignant melanoma with a maximum thickness of16 
mm. Additional re-excision with 1.5 cm safety margins has been 
planned. Immunohistopathological stainings with HMB-45 (diffusely 
positive) and S-100 have shown a strong positive reaction. The 
patient denied sentinel lymph node biopsy. Tumour was staged as 
IIB (T4aN0M0). 1b, 1c, 1d, 1e, 1g, 1h) Surgical removal of the 
tumour, coagulation with single subcutaneous stitches and 
electrocoagulation. Adaptation of the wound’s edges. 1f) 
Achromatic melanoma, measuring approximately the size of a fist. 
Postoperative finding 
 
If the newly recommended by us surgical 
approach were performed initially, the second 
excisions would have been avoided, and the 
performance of the sentinel lymph node removal has 
to be applied in one and the same session.  
 
Figure 2: 2а) Patient with heel melanoma and delayed re-excision, 
developing distant metastasis. 2b) Determination of the surgical 
field. 2c) Intraoperative findings. 2d) Postoperative findings.  
 
Disadvantages: The patient comes 2 months 
later for excision with sentinel lymph node evaluation 
performance. 
 
Figure 3: 3a, 3b) A patient with a verrucous keratotic form of 
melanoma located on the inside of the upper limb.  3c, 3e, 3f, 3g) 
Gradual detoxification of the tumour tissue in depth, accompanied 
by ligation of vena safe manga. 3d) Postoperative findings; 3x, 3i, 
3j) Staging suture and drainage placement 
 
The disadvantages of the AJCC standards 
methodology lies in two main facts: 1)  Need for re-
excision after tumour thicknesses measurement; 2) 
Conducting of the drainage lymph node removal, as 
well as the possibility of it being falsely negative due 
to the extensive excision. 3) After an ultrasound 
examination of the loco regional lymph nodes and the 
exclusion of the possible metastases spread, the 
patient did not appear for re-examinаtion and sentinel 
lymph node removal. 
Disadvantages of the applied approach: The 
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patient did not appear either for re-excision or the 
evaluation of the sentinel lymph node. The question 
whether a wider initial excision combined with sentinel 
lymph node removal would be more benefit in this 
type of patients remains open. Certainly, these 
criteria, namely the AJCC’s, create prerequisites for 
generating different problems. 
Recommendations and advantages of the 
proposed by us method or clinical approach: 
Mandatory ultrasonographically measurement of 
tumour thickness and removal of the draining lymph 
node simultaneously with the single primary excision 
with at least 2 cm surgical safety field would be a 
wonderful solution for the benefit of the patients. Thus, 
neither the patient nor the therapist could act 
improperly. 
 
 
Discussion 
 
We present 3 patients with melanomas with a 
tumour thickness of 2 mm or more. The terms 
“variability” and “positioning” are discussed, concepts 
that need rethinking and strict follow-up, at least when 
it comes to patients with skin melanoma. 
We highlight the essential need for stricter 
guidelines for surgical treatment of melanoma as a 
whole and in particular for AJCC’s guideline 
refurbishment in future periods as the variability of 
current recommendations does not create optimal 
conditions for an initial surgical approach and could 
lead to poor prognosis in some patients. The surgical 
approach should be more radical about melanoma 
patients. The approach should be combined and may 
be shortened as some procedures when the draining 
lymph node is removed within one surgical session in 
parallel with the initial excision adjusted to the 
measured ultrasound tumour thickness. 
The "freedom of action" in the surgical 
treatment of cutaneous melanoma, which is provided 
as a type of recommendation in the AJCC postulates, 
should be rethought and re-formulated for a more 
aggressive initial approach or choice of clinical 
behaviour (larger fields of surgical safety margins to 
be clearly defined). This freedom about the 
determination of the surgical margins is at least or 
somewhat confusing and misleading and does not 
answer the question: 
Why do we treat melanomas in different 
stages, with significant differences in 
tumour thickness in the same way? 
But this gives a very good, though rather 
probable or hypothetical answer to the question: Why 
do patients at different stages have the same 
prognosis or why do patients with the same stages 
have different prognosis?  
Creating problems that we can solve is a well-
known method of antiquity for governing the masses 
in obedience. Interesting, but also the tragic thing 
about creating these guidelines in medicine is that it 
creates unnecessary problems and dividing lines, 
questions with many unknowns, which at a later stage 
could not be solved, or at least resolved with a 
favourable outcome. 
We would appeal to the AJCC 2011 
melanoma’s experts and creators of the guideline with 
a few key questions (as we will be very happy and 
flattered if the experts’ group answers or comments 
on each point): 
1) Why ultrasound measurement of tumour 
thickness is not a standard procedure in patients with 
melanoma suspicion? Wouldn’t this optimise the 
subsequent therapeutic approach? 
2) Why is the primary excision not combined 
with the parallel removal of the sentinel lymph node? 
Moreover, sentinel lymph node removal is already 
recommended for tumours with a thickness less than 
1 mm or even less than 0,75mm, according to some 
literary data? 
3) Why aggressive melanomas with a 
thickness less than 1 mm should be removed with a 
surgical field of 1 cm- namely, the resection zone 
equivalent to melanoma in situ (a choice of 0.5 to 1 
cm)? And for tumours less than 1 mm in thickness, 
with additional aggressive criteria, a sentinel lymph 
node is removed? Is the prognosis for these two 
conditions identical? And why is the approach, let’s 
say, at least identical? 
4) Don’t you think that all these facts impose a 
"recent promulgation", "calling an experts’ council / or 
an expert group” to optimise the melanoma’s surgical 
approach? 
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